ARA-290
ARA-290 (Cibinetide)
ARA-290 (Cibinetide) is an 11-amino acid peptide engineered from the helix B domain of erythropoietin (EPO). Endurance athletes know EPO for its ability to build red blood cells, but that mechanism comes with dangerous blood-thickening side effects. Researchers specifically designed ARA-290 to strip out the red blood cell production while keeping EPO's massive tissue repair and neuroprotective properties. We are looking at a highly targeted tool for nerve damage and chronic systemic inflammation.
Buy ARA-290 at Peptide PalacePurity
99%+
Molecular Weight
1257.3 g/mol
Administration
Subcutaneous injection
Storage
Store lyophilized powder at -20°C
Mechanism of Action
ARA-290 selectively targets the Innate Repair Receptor (IRR), a heterocomplex made of the EPO receptor and the CD131 subunit. This specific receptor only activates when tissues are physically stressed, inflamed, or damaged. Binding to the IRR shuts off pro-inflammatory cytokine production and physically stimulates nerve axon growth. Because it has zero affinity for the standard EPO homodimer receptor, it cannot stimulate erythropoiesis or raise your hematocrit.
Sequence:
pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser Chemical Structure
Research Areas
- Small fiber neuropathy
- Diabetic neuropathy
- Systemic inflammation and sarcoidosis
- Axonal nerve regeneration
- Metabolic syndrome and insulin resistance
Potential Benefits
- Stimulates regrowth of damaged small nerve fibers
- Significantly reduces neuropathic pain
- Blunts systemic inflammatory markers
- Protects cells from apoptosis during ischemic events
- Improves metabolic control in diabetic models
Research Dosing Guidelines
For research purposes only. Not for human consumption.
Typical Dose
2 mg - 4 mg (2000-4000 mcg)
Frequency
Once daily
Duration
4 to 8 weeks
Administration
Subcutaneous injection
The clinical trials for small fiber neuropathy used 4mg daily for 28 days to achieve nerve regrowth. The community typically runs 2mg to 4mg daily. Because it targets nerve repair specifically, many researchers stack it with BPC-157 or TB-500 when dealing with severe sciatica or nerve impingements.
Reconstitution Calculator
U-100 Insulin Syringe
0.1 units
2500 mcg/ml
0.0008 ml
0.1 IU
2500
For research and educational purposes only. Always follow proper reconstitution and sterile handling protocols.
ARA-290 vs Erythropoietin: A Critical Distinction
ARA-290 was specifically engineered to separate EPO's tissue-protective properties from its dangerous blood-thickening effects. Understanding this distinction is essential for safe research.
EPO vs ARA-290
| Factor | ARA-290 (Cibinetide) | Erythropoietin (EPO) |
|---|---|---|
| Red blood cell production | None | Significant (primary effect) |
| Tissue protection | Yes (via Innate Repair Receptor) | Yes (via both receptor types) |
| Nerve regeneration | Strong | Moderate |
| Blood thickening risk | None | Major safety concern |
| Anti-inflammatory | Potent | Moderate |
| Clinical evidence | Phase II trials (neuropathy) | Decades of clinical use |
ARA-290 selectively binds only the Innate Repair Receptor (EPO-R/CD131 heterocomplex), which activates exclusively in stressed or damaged tissues. This makes it incapable of stimulating erythropoiesis or raising hematocrit levels.
Potential Side Effects
- Mild injection site redness
- Transient headaches
- Mild fatigue during the first week
Storage Requirements
Store lyophilized powder at -20°C. Once reconstituted, keep refrigerated at 2-8°C and use within 14 days.
Research References
- [1]ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber neuropathy (2013)Strong Evidence Population: Sarcoidosis patients with small fiber neuropathy (n=22)
ARA-290 administration significantly reduced neuropathic pain and improved quality of life in sarcoidosis patients.
Limitations: Small sample size; open-label design for some endpoints
- [2]ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic pain in patients with type 2 diabetes (2014)Strong Evidence Population: Type 2 diabetes patients with neuropathy (n=48)
A 28-day protocol of ARA-290 improved HbA1c levels and reduced neuropathic pain symptoms in diabetic patients.
Limitations: Short 28-day treatment period; single-center study
- [3]ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain (2014)Emerging Evidence Population: Rats with chronic constriction injury
The peptide blocked macrophage activation and provided long-term relief from neuropathic pain in peripheral nerve injury models.
Limitations: Animal model; extrapolation to human chronic pain uncertain
Frequently Asked Questions
What is ARA-290?
ARA-290 is an 11-amino acid peptide derived from erythropoietin (EPO). It was explicitly engineered to harness EPO's tissue repair and nerve regeneration properties without triggering red blood cell production. This makes it a highly specialized research compound for treating neuropathy and chronic inflammation.
What are the potential research benefits of ARA-290?
The primary benefit is nerve regeneration, specifically the regrowth of small nerve fibers damaged by diabetes, autoimmune disease, or physical trauma. It also powerfully downregulates systemic inflammation and reduces neuropathic pain. Some metabolic data shows it can improve insulin sensitivity and lower HbA1c.
How is ARA-290 typically dosed in research?
Clinical trials demonstrating actual nerve regrowth successfully used 4mg (4000 mcg) administered once daily. In the research community, standard protocols range from 2mg to 4mg injected subcutaneously every day. Cycles generally last 4 to 8 weeks depending on the severity of the neuropathy.
What are the side effects of ARA-290?
The safety profile is exceptional because it does not bind to the receptors that cause blood thickening. Reported side effects are minimal and usually limited to mild injection site redness or transient headaches. It does not alter blood pressure or hematocrit levels.
How should ARA-290 be stored?
Store the lyophilized powder in the freezer at -20°C for long-term stability. Once reconstituted with bacteriostatic water, keep the vial in the refrigerator at 2-8°C and use within two weeks.
Ready to Purchase ARA-290?
Get the highest quality ARA-290 from our recommended vendor with 99%+ purity guaranteed.
Buy at Peptide PalaceRelated Topics
Therapeutic Applications of Peptides
Therapeutic peptides occupy the pharmacological space between small molecules and biologics, offering high selectivity for protein-protein interactions with lower immunogenicity.
Bioactive Peptides and Signaling Pathways
Bioactive peptides regulate physiology through GPCR and receptor tyrosine kinase signaling, functioning as hormones, neurotransmitters, and local mediators.
Safety & Reference
Related Peptides
BPC-157
Body Protection Compound-157
BPC-157 is a pentadecapeptide composed of 15 amino acids. It is a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice. Research has shown it accelerates the healing of many different wounds, including tendon-to-bone healing and superior healing of damaged ligaments.
Learn MoreTB-500
Thymosin Beta-4
TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4. It plays a crucial role in tissue repair, regeneration, and protection. TB-500 is known for its ability to promote healing, reduce inflammation, and improve flexibility.
Learn MoreDihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa is a potent oligopeptide derived from angiotensin IV that has demonstrated remarkable cognitive-enhancing and neuroprotective properties. Originally developed at Washington State University, it is considered up to ten million times more potent than BDNF at forming new neural connections in research models.
Learn More